31-Oct-2026 15:05:04
KOTAK ON ALIVUS LIFE SCIENCES ; BUY | TP ₹1,630 (EARLIER ₹1,400)
• Kotak maintains Buy rating on Alivus Life Sciences and raises target price to ₹1,630 from ₹1,400. • Q2 EBITDA beats estimates, supported by better product mi…
Latest market headlines for ALIVUS on Terminal.
31-Oct-2026 15:05:04
• Kotak maintains Buy rating on Alivus Life Sciences and raises target price to ₹1,630 from ₹1,400. • Q2 EBITDA beats estimates, supported by better product mi…
30-Oct-2026 16:54:35
• **FY27 Revenue Guidance:** Management reiterated its revenue growth guidance of 10–12%, supported by new product launches, generic API demand and CDMO growth…
29-Oct-2026 19:23:36
REVENUE UP 16% AT ₹682 CR (YOY), UP 6% (QOQ) EBITDA UP 48% AT ₹265 CR (YOY), UP 25% (QOQ) MARGINS AT 38.9% VS 30.5% (YOY), 33.1% (QOQ)
29-Oct-2026 19:23:07
REVENUE UP 16% AT ₹682 CR (YOY), UP 6% (QOQ) EBITDA UP 48% AT ₹265 CR (YOY), UP 25% (QOQ) MARGINS AT 38.9% VS 30.5% (YOY), 33.1% (QOQ)
29-Oct-2026 19:22:48
• Revenue up 16.0% at ₹682 Cr YoY, up 6.5% QoQ. • PBT up 50.4% at ₹262 Cr YoY, up 23.4% QoQ. • PBT margin 38.4% vs 29.6% YoY, 33.1% QoQ. • PAT margin 28.8% vs…
07-Oct-2026 17:18:44
ALIVUS LIFE SCIENCES : TORRENT URJA 19 PRIVATE LIMITED STEP-DOWN SUBSIDIARY ACQUIRES 9.21% EQUITY
16-Sept-2026 13:17:25
• Alivus Life Sciences Do Brasil Ltda. incorporated in the state of Sao Paulo, Brazil on September 15, 2026. • The subsidiary is a wholly owned subsidiary of A…
18-Aug-2026 17:30:29
• Alivus Life Sciences Limited Board of Directors approved the share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited for an aggregate…